Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Modality
Cell therapy
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05020392CT.gov Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Burkitt Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cart-19 Cells (this asset) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | P3 | B · 57 |
| Nivestim | Fred Hutchinson Cancer Center | P4 | BBB |
| Vincristine Sulfate | AIDS Malignancy Consortium | P2 | BBB |
| Vindesine | PETHEMA Foundation | P4 | BBB |
| Cyclophosphamide | AIDS Malignancy Consortium | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Cytarabine | AIDS Malignancy Consortium | P4 | BBB |
| Romidepsin | M.D. Anderson Cancer Center | P2 | BBB |
| Adriamycin | AIDS Malignancy Consortium | P4 | BBB |
+42 more in the Burkitt Lymphoma cohort
Other indications for Cart-19 Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P2/3 | BB · 64 |
| B-Cell Acute Lymphoblastic Leukemia | — | P2/3 | B · 61 |
| Acute Lymphoblastic Leukemia | — | P1/2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cart-19 Cells in Burkitt Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cart-19-cells-burkitt-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →